Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SZ003 in Advanced Hepatocellular Carcinoma
NCT05845502Phase 1Terminated
- Sponsor
- Shantou University Medical College
- Start
- Jul 2021
- Primary completion
- Sep 2024
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SZ003 in hepatocellular carcinoma (HCC), sponsored by Shantou University Medical College. Primary endpoint: Incidence rates and severity of Adverse Events at 1 year. Started Jul 2021; status: terminated.
02
Drugs
SZ003
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05845502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845502.